The Nocebo Effect in a Non-Medical Switching Program from Originator to Biosimilar Infliximab in Inflammatory Bowel Disease

Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study

(2020) Craig Haifer et al.   MEDICAL JOURNAL OF AUSTRALIA

Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

(2019) Christopher Ma et al.   Journal of Crohns & Colitis

Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease

(2019) M Chaparro et al.   Journal of Crohns & Colitis

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

(2017) Kristin K Jørgensen et al.   LANCET

Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab

(2017) Lieke Tweehuysen et al.   Arthritis & Rheumatology

Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-Control questionnaire

(2013) Keith Bodger et al.   GUT